Living with HT-1
We now have a new option to treat hereditary tyrosinemia (HT-1). This new medication, NITYR (nitisinone) tablets, may give adolescents and adults living with HT-1, a more convenient choice in treatment.
HT-1 treatment has not advanced at the same rate as that of more common diseases. Cycle Pharmaceuticals truly believes HT-1 patients deserve more. We’ve been working for years to develop a more convenient formulation of nitisinone (NTBC), one that may offer many potential advantages to patients.
Even if your condition is well controlled on your current nitisinone therapy, this new formulation aims to make your life easier and improve quality of life. If you are considering NITYR, speak to your HCP, your dietitian or your clinic today – you don’t need to wait until your next appointment. To support the discussion we’ve gathered some common questions patients ask in our Consultation Guide, which you can download here.